Hepatic‐Portal Vein Infusions of Glucagon‐Like Peptide‐1 Reduce Meal Size and Increase c‐Fos Expression in the Nucleus Tractus Solitarii, Area Postrema and Central Nucleus of the Amygdala in Rats
Open accessAbstract
We recently reported that brief, remotely controlled intrameal hepatic‐portal vein infusions of glucagon‐like peptide‐1 (GLP‐1) reduced spontaneous meal size in rats. To investigate the neurobehavioural correlates of this effect, we equipped male Sprague‐Dawley rats with hepatic‐portal vein catheters and assessed (i) the effect on eating of remotely triggered infusions of GLP‐1 (1 nmol/kg, 5 min) or vehicle during the first nocturnal meal after 3 h of food deprivation and (ii) the effect of identical infusions performed at dark onset on c‐Fos expression in several brain areas involved in the control of eating. GLP‐1 reduced (P < 0.05) the size of the first nocturnal meal and increased its satiety ratio. Also, GLP‐1 increased (P < 0.05) the number of c‐Fos‐expressing cells in the nucleus tractus solitarii, the area postrema and the central nucleus of the amygdala, but not in the arcuate or paraventricular hypothalamic nuclei. These data suggest that the nucleus tractus solitarii, the area postrema and the central nucleus of the amygdala play a role in the eating‐inhibitory actions of GLP‐1 infused into the hepatic‐portal vein; it remains to be established whether activation of these brain nuclei reflect satiation, aversion, or both.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An alternative explanation for GI symptoms is direct interaction of GLP-1RAs with GLP-1R in brain regions such as the brainstem (area postrema, nucleus tractus solitarii), which are not protected by the blood-brain barrier and are typically involved in medication-induced nausea.
“an alternative explanation, albeit not mutually exclusive, is direct interaction of GLP-1RAs with GLP-1R in brain regions such as the brainstem (area postrema, nucleus tractus solitarii), which are not protected by the blood-brain barrier, and are typically involved in medication-induced nausea (chemosensitive area) (54–56).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [54]
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429 · see citing works
Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · see citing works
Yamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · see citing works
Self-citationPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498 · see citing works
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · see citing works
Self-citationRole of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269 · see citing works
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248 · see citing works
Suchankova, P., Yan, J., Schwandt, M. L., Stangl, B. L., Caparelli, E. C., Momenan, R., Jerlhag, E., Engel, J. A., Hodgkinson, C. A., Egli, M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.68 · Cited by 146 · see citing works
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146 · see citing works
Ronveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124 · see citing works
Parker, J. A., McCullough, K. A., Field, B. C. T., Minnion, J. S., Martin, N. M., Ghatei, M. A., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.227 · Cited by 111 · see citing works
Krieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91 · see citing works
Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
Baraboi, E.-D., St-Pierre, D. H., Shooner, J., Timofeeva, E., & Richard, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00424.2010 · Cited by 79 · see citing works
Punjabi, M., Arnold, M., Rüttimann, E., Graber, M., Geary, N., Pacheco-López, G., & Langhans, W. (2014) · Endocrinology · doi:10.1210/en.2013-1447 · Cited by 59 · see citing works
Nutrition and l and K-enteroendocrine cells
Gutierrez-Aguilar, R., & Woods, S. C. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32834190b5 · Cited by 47 · see citing works
Dagbasi, A., Lett, A. M., Murphy, K., & Frost, G. (2020) · Proceedings of the Nutrition Society · doi:10.1017/s0029665120006941 · Cited by 44 · see citing works
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40 · see citing works
- Authors
- Baumgartner, I., Pacheco‐López, G., Rüttimann, E. B., Arnold, M., Asarian, L., Langhans, W., Geary, N., & Hillebrand, J. J. G.
- Affiliations
- ETH Zurich (CH)
- Corresponding author
- Hillebrand, J. J. G.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2010-05-18
- Volume
- 22
- Issue
- 6
- Pages
- 557-563
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- OpenAlex
- W2125461254
- Cited by
- 64
- References
- 4
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 6 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 6 · 2014: 5 · 2013: 9 · 2012: 6
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.zora.uzh.ch
- Licence
- Locations
- Journal of Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- BORIS (University Library Bern) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, meal size, satiety, Fos expression, nucleus tractus solitarius, area postrema, central amygdala, hypothalamic nuclei, food intake regulation, satiation, aversion, food deprivation
- MeSH terms
- Amygdala, Animals, Feeding Behavior, Immunohistochemistry, Male, Portal Vein, Proto-Oncogene Proteins c-fos, Rats, Sprague-Dawley, Solitary Nucleus, Area Postrema, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
